Which factors have an impact on levetiracetam serum concentrations? An analysis in 163 patients with epilepsy;Welche faktoren beeinflussen die serumkonzentration von levetiracetam? Eine analyse bei 163 patienten mit epilepsie

Nervenarzt

Volumn 81, Issue 4, 2010, Pages 391-395

  Bauer, J ^a   Pfeiffer, C ^a   Burr, W ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Antiepileptic drugs; Epilepsy; Levetiracetam; Pharmacotherapy

Indexed keywords

CARBAMAZEPINE; CLOBAZAM; ETIRACETAM; OXCARBAZEPINE; VALPROIC ACID;

ADULT; BLOOD SAMPLING; CLINICAL ASSESSMENT; COMPARATIVE STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; EPILEPSY; EXTRACTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PATIENT COMPLIANCE; REVIEW; TREATMENT DURATION; TREATMENT INDICATION;

ADULT; ANALYSIS OF VARIANCE; ANTICONVULSANTS; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; HUMANS; LINEAR MODELS; MALE; METABOLIC CLEARANCE RATE; PIRACETAM; STATISTICS AS TOPIC;

EID: 77953622492     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-009-2906-y     Document Type: Review

References (13)

1. Bauer J, Hermann A, Reuber M (2002) Verträglichkeit einer hochdosierten Monotherapie mit Carbamazepin in der Epilepsiebehandlung. Nervenarzt 73:533-537
2. Bauer J, Ben-Menachem E, Krämer G et al (2006) Levetiracetam: a long-term follow-up study of efficacy and safety. Acta Neurol Scand 114:169-176
3. Brandt C, Baumann P, Eckermann G et al (2008) Therapeutic drug monitoring in Epileptologie und Psychiatrie. Nervenarzt 79:167-174
4. Coupez R, Nicolas J-M, Browne TR (2003) Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic interaction with valproic acid. Epilepsia 44:171-178
5. Lynch BA, Lambeng N, Nocka K et al (2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 101:9861-9866
6. May TW, Rambeck B, Jürgens U (2003) Serum concentrations of levetiracetam in epileptic patients: the influence of dose and co-medication. Ther Drug Monit 25:690-699
7. Perucca E (1996) The new generation of antiepileptic drugs: advantages and disadvantages. Br J Clin Pharmacol 42:531-543 (Pubitemid 26385257)
8. Perucca E (2000) Is there a role for therapeutic drug monitoring of new anticonvulsants? Clin Pharmakokin 38:191-204
9. Radtke RA (2001) Pharmacokinetics of levetiracetam. Epilepsia 42 [Suppl 4]:24-27
10. Ragueneau-Majlessi I, Levy HR, Janik F (2002) Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women. Epilepsia 43:697-702
11. Rambeck B, Jürgens UH, May TW et al (2006) Comparison of brain extracellular fluid, brain tissue, cerebrospial fluid and serum concentrations of antiepileptic drugs measures intraoperatively in patients with intractable epilepsy. Epilepsia 47:681-694
12. Schulz M, Schmoldt A (2003) Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Pharmazie 58:447-474
13. Specht U (2008) Medikamenten-Compliance bei Epilepsie. Nervenarzt 79:662-668